IKT INHIBIKASE THERAPEUTICS INC Company Mergers 8-K Filing 2025 - Merger Agreement On February 21, 2025, Inhibikase Therapeutics acquired CorHepta Pharmaceuticals for $15 million, issuing 4,979,101 shares as payment, and appointed Chris Cabell as President and Head of R&D.Get access to all SEC 8-K filings of the INHIBIKASE THERAPEUTICS INC